10-Q · May 15, 2026
Lantern Pharma reported Q1 results for FY 2026 with an adjusted EPS loss of -$0.36, slightly better than the estimated loss of -$0.45. The company continues to face challenges with zero revenue generation during the…
Earnings analysis · 10-Q
LTRN earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt contains controls-and-procedures and other-information disclosures but does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment results. Accordingly, revenue,…
Read full summary
The provided 10-Q excerpt contains controls-and-procedures and other-information disclosures but does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment results. Accordingly, revenue, margins, EPS, cash flow, balance-sheet trends, and quantitative guidance cannot be assessed from the supplied filing text. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
-
No material control changes
The company reported no changes in internal control over financial reporting during the three months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, those controls.
What to watch
-
Internal-control limitations
The company states that its controls provide only reasonable, not absolute, assurance; errors or fraud may remain undetected because of limitations including mistake, collusion, management override, and resource constraints.
-
Risk-factor disclosure is limited
As a Smaller Reporting Company, Lantern is exempt from Item 1A risk-factor disclosure, limiting the filing's update on material business, liquidity, and financing risks.
Management's outlook
No quantitative revenue or EPS outlook is disclosed in the provided 10-Q text. The filing does not provide a prior-outlook comparison.
Earlier filings 4
10-K · April 30, 2026
Lantern Pharma's 10-K for fiscal 2025 reveals persistent financial challenges but a focus on AI-driven precision therapeutics. Revenue generation remains a critical gap, while leadership changes and ongoing FDA…
10-K · March 30, 2026
Lantern Pharma positions itself as an AI-driven precision oncology company centered on its RADR® platform (now >200 billion data points and 200+ ML algorithms) to 'rescue' historical small molecules and develop de-novo…
10-K · March 27, 2025
Lantern Pharma positions itself as an AI-driven precision oncology company leveraging its RADR® platform ("more than 100 billion data points") to 'rescue' prior drug candidates and advance de-novo programs; it currently…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.